Neurocrine Biosciences | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Acadia Pharmaceuticals USD 681.58M 74.42M 2025-03
Agios Pharmaceuticals USD 78.96M 2.72M 2025-03
ALKERMES USD 399.81M 108.66M 2025-03
Alnylam Pharmaceuticals USD 1.02B 53.23M 2025-03
Amgen USD 8.81B 3.16B 2025-03
Biogen USD 2.6B 223.3M 2025-03
BioMarin Pharmaceutical USD 612.03M 1.19M 2025-03
Cytokinetics USD 938.22M 843.36M 2025-03
Dynavax Technologies USD 661.34M 565.45M 2025-03
Exelixis USD 183.75M 33.62M 2025-04
Gilead Sciences USD 7.93B 2.06B 2025-03
Halozyme Therapeutics USD 176.33M 60.48M 2025-03
Incyte USD 2.41B 720.83M 2025-03
Ionis Pharmaceuticals USD 264.19M 22.12M 2025-03
Neurocrine Biosciences USD 233M 116.1M 2024-12
Pfizer USD 1.43B 387M 2025-03
Prothena USD 471.39M 47.87M 2024-12
Regeneron Pharmaceuticals USD 3.09B 14.82B 2025-03
Repligen USD 697.23M 60.13M 2025-03
Sarepta Therapeutics USD 240.87M 862.14M 2025-03
Teva Pharmaceutical Industries USD 1.7B 1.6B 2025-03
Ultragenyx Pharmaceutical USD 563M 389.27M 2025-03
Vertex Pharmaceuticals USD 4.57B 669.6M 2024-12



Neurocrine Biosciences Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - May 2025.